Abstract
Purpose
Methotrexate (MTX) is one of the most widely studied and effective therapeutics agents available to treat many solid tumors, hematologic malignancies, and autoimmune diseases such as rheumatoid arthritis; however, the poor pharmacokinetic and narrow safety margin of the drug limits the therapeutic outcomes of conventional drug delivery systems. For an improved delivery of MTX, several pathophysiological features such as angiogenesis, enhanced permeability and retention effects, acidosis, and expression of specific antigens and receptors can be used either as targets or as tools for drug delivery.
Methods
There are many novel delivery systems developed to improve the pitfalls of MTX therapy ranged from polymeric conjugates such as human serum albumin, liposomes, microspheres, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, polymeric micelles, in situ forming hydrogels, carrier erythrocyte, and nanotechnology-based vehicles such as carbon nanotubes, magnetic nanoparticles, and gold nanoparticles. Some are further modified with targeting ligands for active targeting purposes.
Results
Such delivery systems provide prolonged plasma profile, enhanced and specific activity in vitro and in vivo in animal models. Nevertheless, more complementary studies are needed before they can be applied in human.
Conclusion
This review deals with the challenges of conventional systems and achievements of each pharmaceutical class of novel drug delivery vehicle.
Similar content being viewed by others
References
Purcell WT, Ettinger DS (2003) Novel antifolate drugs. Curr Oncol Rep 5(2):114–125
Bleyer WA (1978) The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41(1):36–51
Grim J, Chladek J, Martinkova J (2003) Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 42(2):139–151
Cutolo M et al (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60(8):729–735
Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903–911
Tarner IH, Müller-Ladner U (2008) Drug delivery systems for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 5(9):1027–1037
Rahman LK, Chhabra SR (1988) The chemistry of methotrexate and its analogues. Med Res Rev 8(1):95–155
Chatterji DC, Gallelli JF (1978) Thermal and photolytic decomposition of methotrexate in aqueous solutions. J Pharm Sci 67(4):526–531
Genestier L et al (2000) Mechanisms of action of methotrexate. Immunopharmacology 47(2–3):247–257
Cutolo M et al (2000) Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 27(11):2551–2557
Hillson JL, Furst DE (1997) Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design. Rheum Dis Clin North Am 23(4):757–778
Cronstein BN (1997) The mechanism of action of methotrexate. Rheum Dis Clin North Am 23(4):739–755
Paxton JW (1982) The protein binding and elimination of methotrexate after intravenous infusions in cancer patients. Clin Exp Pharmacol Physiol 9(3):225–234
Bleyer WA, Nelson JA, Kamen BA (1997) Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol 19(6):530–532
Creaven PJ et al (1973) Methotrexate in liver and bile after intravenous dosage in man. Br J Cancer 28(6):589–591
Iqbal MP (1998) Accumulation of methotrexate in human tissues following high-dose methotrexate therapy. J Pak Med Assoc 48(11):341–343
Fiehn C (2010) Methotrexate transport mechanisms: the basis for targeted drug delivery and beta-folate-receptor-specific treatment. Clinical and Experimental Rheumatology. 28(5): S40-S45
Edno L et al (1996) Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Ther Drug Monit 18(2):128–134
Whitehead VM et al (2005) Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a pediatric oncology group study. Leukemia 19(4):533–536
Visser K, van der Heijde DM (2009) Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 27(6):1017–1025
van Ede AE et al (1998) Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27(5):277–292
Koch AE, Distler O (2007) Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S3
Koning GA et al (2006) Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum 54(4):1198–1208
Gaffo A, Saag KG, Curtis JR (2006) Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63(24):2451–2465
Levick JR (1981) Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 24(12):1550–1560
Levick JR (1995) Microvascular architecture and exchange in synovial joints. Microcirculation 2(3):217–233
Levick JR (1990) Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure. J Rheumatol 17(5):579–582
Halin C, Neri D (2001) Antibody-based targeting of angiogenesis. Crit Rev Ther Drug Carrier Syst 18(3):299–339
Nagai T et al (2006) In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells. Arthritis Rheum 54(10):3126–3134
Trachsel E et al (2007) Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 9(1):R9
Stehle G et al (1999) Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats. Anticancer Drugs 10(4):405–411
Wunder A et al (1998) Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer 76(6):884–890
Wunder A et al (2003) Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 170(9):4793–4801
Nakashima-Matsushita N et al (1999) Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42(8):1609–1616
Fiehn C et al (2004) Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford) 43(9):1097–1105
Fiehn C et al (2008) Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Annals Rheum Dis 67(8):1188–1191
Han J et al (2001) Altered pharmacokinetics and liver targetability of methotrexate by conjugation with lactosylated albumins. Drug Deliv J Deliv Target Therapeutic Agents 8(3):125–134
Han JH et al (1999) Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. Int J Pharm 188(1):39–47
Chau Y, Tan FE, Langer R (2004) Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug Chem 15(4):931–941
Chau Y et al (2006) Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model. J Pharm Sci 95(3):542–551
Nevozhay D et al (2006) The effect of the substitution level of some dextran-methotrexate conjugates on their antitumor activity in experimental cancer models. Anticancer Res 26(3A):2179–2186
Nevozhay D et al (2006) Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier. Anticancer Res 26(2A):1135–1143
Yousefi G et al (2010) Synthesis and characterization of methotrexate polyethylene glycol esters as a drug delivery system. Chem Pharm Bull (Tokyo) 58(2):147–153
Shukla G et al (2008) Polyethylene glycol conjugates of methotrexate and melphalan: synthesis, radiolabeling and biologic studies. Cancer Biother Radiopharm 23(5):571–579
Riebeseel K et al (2002) Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo. Bioconjug Chem 13(4):773–785
Homma A et al (2009) Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment. Bioorg Med Chem 17(13):4647–4656
Homma A et al (2012) Synthesis and optimization of hyaluronic acid-methotrexate conjugates to maximize benefit in the treatment of osteoarthritis. Bioorganic Med Chem 18(3):1062–1075
Bowman BJ, Ofner Iii CM (2000) Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity. Pharm Res. 17(10):1309–1315
Smith GK et al (1997) Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J Biol Chem 272(25):15804–15816
Ou XH et al (2004) Receptor binding characteristics and cytotoxicity of insulin-methotrexate. World J Gastroenterol 10(16):2430–2433
Lindgren M et al (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71(4):416–425
Wu Z et al (2012) Development of methotrexate proline prodrug to overcome resistance by MDA-MB-231 cells. Bioorganic Med Chem Lett 20(17):5108–5112
Hudecz F et al (1993) Influence of carrier on biodistribution and in vitro cytotoxicity of methotrexate-branched polypeptide conjugates. Bioconjug Chem 4(1):25–33
Williams AS et al (1995) Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis. Clin Exp Immunol 102(3):560–565
Williams AS et al (1996) A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Br J Rheumatol 35(8):719–724
Williams AS et al (2001) Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression. Rheumatology (Oxford) 40(4):375–383
Metselaar JM et al (2004) Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 63(4):348–353
Metselaar JM et al (2003) Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 48(7):2059–2066
Hong MS et al (2001) Prolonged blood circulation of methotrexate by modulation of liposomal composition. Drug Deliv 8(4):231–237
Prabhu P et al (2012) Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int J Nanomed 7:177–186
Pignatello R et al (2005) Lipophilic conjugates of methotrexate with glucosyl-lipoamino acids: calorimetric study of the interaction with a biomembrane model. Thermochim Acta 426(1–2):163–171
Pignatello R et al (2003) Effect of liposomal delivery on in vitro antitumor activity of lipophilic conjugates of methotrexate with lipoamino acids. Drug Deliv 10(2):95–100
Pignatello R et al (2001) Lipophilic methotrexate conjugates with glucose-lipoamino acid moieties: synthesis and in vitro antitumor activity. Drug Develop Res 52(3):454–461
Kuznetsova N et al (2009) Liposomes loaded with lipophilic prodrugs of methotrexate and melphalan as convenient drug delivery vehicles. J Drug Deliv Sci Technol 19(1):51–59
Timothy DH et al (1983) Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma aspartate. Proc Natl Acad Sci U S A 80:1377–1381
Singh M et al (1989) Targeting of methotrexate-containing liposomes with a monoclonal antibody against human renal cancer. Cancer Res 49(14):3976–3984
Singh M et al (1991) Inhibition of human renal cancer by monoclonal antibody targeted methotrexate-containing liposomes in an ascites tumor model. Cancer Lett 56(2):97–102
Oommen E et al (1999) Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system. Indian J Pharmacol 31(4):279–284
Sheena IP et al (1997) Niosomal entrapment of hydroxypropyl-β-cylodextrin-methotrexate complex as a drug delivery device. Pharm Sci 3(12):579–582
Singh UV, Udupa N (1997) In vitro characterization of methotrexate loaded poly(lactic-co-glycolic) acid microspheres and antitumor efficacy in Sarcoma-180 mice bearing tumor. Pharm Acta Helv 72(3):165–173
Singh UV et al (1997) Preparation, characterization, and antitumor efficacy of biodegradable poly(lactic acid) methotrexate implantable films. Drug Deliv 4(2):101–106
Singh UV, Udupa N (1998) In vitro characterization of methotrexate-loaded poly(lactic acid) microspheres of different molecular weights. Drug Deliv J Deliv Targeting Therapeutic Agents 5(1):57–61
Liang LS et al (2004) Methotrexate loaded poly(l-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J Pharm Sci 93(4):943–956
Narayani R, Panduranga Rao K (1993) Preparation, characterisation and in vitro stability of hydrophilic gelatin microspheres using a gelatin-methotrexate conjugate. Int J Pharm 95(1–3):85–91
Narayani R, Panduranga Rao K (1994) Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres. J Microencapsul 11(1):69–77
Narayani R, PandurangaRao K (1995) pH-responsive gelatin microspheres for oral delivery of anticancer drug methotrexate. J Appl Polym Sci 58(10):1761–1769
Narayani R, PandurangaRao K (1996) Solid tumor chemotherapy using injectable gelatin microspheres containing free methotrexate and conjugated methotrexate. Int J Pharm 142(1):25–32
Sun Y et al (2009) The effect of chitosan molecular weight on the characteristics of spray-dried methotrexate-loaded chitosan microspheres for nasal administration. Drug Dev Ind Pharm 35(3):379–386
Sun Y et al (2012) Methotrexate-loaded microspheres for nose to brain delivery: in vitro/in vivo evaluation. J Drug Deliv Sci Technol 22(2):167–174
Taheri A et al (2011) Nanoparticles of conjugated methotrexate-human serum albumin: preparation and cytotoxicity evaluations. J Nanomaterials, Art ID 768201
Taheri A et al (2012) The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. Int JPharm 431(1–2):183–189
Taheri A et al (2012) Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with luteinizing hormone-releasing hormone (LHRH) peptide. Int J Mol Sci 12(7):4591–4608
Taheri A et al (2012) Targeted delivery of methotrexate to tu mor cells using biotin functionalized methotrexate-human serum albumin conjugated nanoparticles. J Biomed Nanotechnol 7(6):743–753
Taheri A et al (2012) Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int J Nanomed 6:1863–1874
Taheri A et al (2012) Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells. Eur J Pharm Sci 47(2):331–340
Jain S et al (2011) Synthesis, pharmacoscintigraphic evaluation and antitumor efficacy of methotrexate-loaded, folate-conjugated, stealth albumin nanoparticles. Nanomedicine (Lond) 6(10):1733–1754
Trapani A et al (2011) Methotrexate-loaded chitosan- and glycol chitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors. AAPS Pharm Sci Tech 12(4):1302–1311
Azadi A et al (2012) Preparation and optimization of surface-treated methotrexate-loaded nanogels intended for brain delivery. Carbohydrate Polym 90(1):462–471
Ji JG et al (2012) Preparation, characterization, and in vitro release of folic acid-conjugated chitosan nanoparticles loaded with methotrexate for targeted delivery. Polym Bull 68(6):1707–1720
Reddy LH, Murthy RR (2004) Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharmaceutica 54(2):103–118
Gao K, Jiang X (2006) Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm 310(1–2):213–219
Cascone MG et al (2002) Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med 13(5):523–526
Kong SY et al. (2008) Preparation and in vitro release of methotrexate complexation with PEGylated dendrimers. Chinese Pharm J. 43(14): 1085 + 1086–1091
Gurdag S et al (2006) Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem 17(2):275–283
Quintana A et al (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19(9):1310–1316
Zong H et al (2012) Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio. Biomacromolecules 13(4):982–991
Choi SK et al (2012) Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate. Photochem Photobiol Sci 11(4):653–660
Shukla R et al (2008) HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology 19(29):7
Kaminskas LM et al (2009) Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm 6(4):1190–1204
Kaminskas LM et al (2010) Capping methotrexate alpha-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. Mol Pharm 8(2):338–349
Kurmi BD et al (2011) Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. J Pharm Sci 100(6):2311–2320
Dhanikula RS et al (2008) Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 5(1):105–116
Dhanikula RS, Hildgen P (2007) Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate. Biomaterials 28(20):3140–3152
Kohler N et al (2006) Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small 2(6):785–792
Kohler N et al (2005) Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 21(19):8858–8864
Zhu L et al (2009) Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm 370(1–2):136–143
Devineni D, Blanton CD, Gallo JM (1995) Preparation and in vitro evaluation of magnetic microsphere-methotrexate conjugate drug delivery systems. Bioconjug Chem 6(2):203–210
Zhang X, Chen F, Ni J (2009) A novel method to prepare magnetite chitosan microspheres conjugated with methotrexate (MTX) for the controlled release of MTX as a magnetic targeting drug delivery system. Drug Deliv 16(5):280–288
Jeong Y et al (2009) Methotrexate-incorporated polymeric micelles composed of methoxy poly(ethyleneglycol)-grafted chitosan. Macromol Res 17(7):538–543
Zhang Y, Jin T, Zhuo RX (2005) Methotrexate-loaded biodegradable polymeric micelles: preparation, physicochemical properties and in vitro drug release. Colloids Surf B Biointerfaces 44(2–3):104–109
Li Y, Kwon GS (1999) Micelle-like structures of poly(ethylene oxide)-block-poly(2- hydroxyethyl aspartamide)-methotrexate conjugates. Colloids Surf B Biointerfaces 16(1–4):217–226
Li Y, Kwon GS (2000) Methotrexate esters of poly(ethylene oxide)-block-poly(2-hydroxyethyl-l-aspartamide). Part I: effects of the level of methotrexate conjugation on the stability of micelles and on drug release. Pharm Res 17(5):607–611
Pluta J, Karolewicz B (2006) In vitro studies of the properties of thermosensitive systems prepared on Pluronic F-127 as vehicles for methotrexate for delivery to solid tumours. Polim Med 36(3):37–53
Miao B, Song C, Ma G (2011) Injectable thermosensitive hydrogels for intra-articular delivery of methotrexate. J Appl Polym Sci 122(3):2139–2145
Karasulu HY et al (2009) Determining the cytotoxicity of methotrexate-loaded microemulsion on human breast, ovarian, and prostate carcinoma cell lines: a new modality for an old drug. Drug Develop Res 70(1):49–56
Karasulu HY et al (2007) Controlled release of methotrexate from w/o microemulsion and its in vitro antitumor activity. Drug Deliv 14(4):225–233
Moura JA et al (2011) Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int J Nanomed 6:2285–2295
Ruckmani K, Sivakumar M, Ganeshkumar PA (2006) Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 6(9–10):2991–2995
Utreja S, Khopade AJ, Jain NK (1999) Lipoprotein-mimicking biovectorized systems for methotrexate delivery. Pharm Acta Helv 73(6):275–279
Yuan SH et al (2009) Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers. Fundam Clin Pharmacol 23(2):189–196
Mishra PR, Jain NK (2000) Surface modified methotrexate loaded erythrocytes for enhanced macrophage uptake. J Drug Target 8(4):217–224
Mishra PR, Jain NK (2002) Biotinylated methotrexate loaded erythrocytes for enhanced liver uptake. ‘A study on the rat’. Int J Pharm 231(2):145–153
Chen YH et al (2007) Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 4(5):713–722
Samori C et al (2010) Enhanced anticancer activity of multi-walled carbon nanotube-methotrexate conjugates using cleavable linkers. Chem Commun 46(9):1494–1496
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abolmaali, S.S., Tamaddon, A.M. & Dinarvand, R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol 71, 1115–1130 (2013). https://doi.org/10.1007/s00280-012-2062-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-012-2062-0